We have recently shown that human prostate cancer (PCa) cells induced apoptotic death of the most potent antigen-presenting cells, dendritic cells (DC), which are responsible for the induction of specific antitumor immune responses. Here we have evaluated the effect of murine PCa cells RM-1 on the survival of immature and tumor necrosis factor-a (TNF-a)-stimulated mature DC. PCa cells and DC were co-incubated for 24 -48 h and DC apoptosis was assessed by morphologic criteria, Annexin V assay, and TUNEL staining. We have shown that co-incubation of RM-1 cells with DC is accompanied by an increased level of DC apoptosis, which was mediated by decreased expression of anti-apoptotic protein Bcl-2. Stimulation of DC maturation by TNF-a resulted in increased resistance of DC to PCa-induced apoptosis. In TNF-a treated mature DC, but not in immature DC, the expression of Bcl-2 was not blocked after exposure to RM-1-derived factors. Thus, these data suggest that TNF-a-induced maturation of DC increases their resistance to PCa induced apoptosis. This is likely to be due to the stabilizing of the expression of anti-apoptotic protein Bcl-2. The difference in the sensitivity of mature and immature DC to PCa-induced cell death should be considered during the design of DC-based clinical trials for PCa patients. Prostate Cancer and Prostatic Diseases (2001) 4, 221-227.
Introduction
Treatment of advanced prostate cancer is still far from satisfactory, especially when the tumor reaches the hormone-resistant state. A low proliferative index makes prostate cancer less sensitive to chemotherapy. However, immunotherapeutic modalities, which do not require high proliferative index of tumor cells, may hold some promise, based on a number of preclinical and first clinical data. On the other hand, occurrence and development of the tumor implies that the neoplastic cells are able to escape the host immune defense system. Tumor cells could be either nonimmunogenic, that is, unrecognizable by the immune system, or could actively suppress the induction and/or development of specific or general immune responses. In fact, prostate cancer cells have often been shown to be weakly immunogenic due to the lack of major histocompatibility complex (MHC) molecules on their surface. 1 Furthermore, tumor-induced immunosuppression was also repeatedly documented in prostate cancer patients. 2, 3 We have recently demonstrated that human prostate cancer cell lines caused apoptosis of dendritic cells (DC), the key regulatory cells of the immune system responsible for the induction of specific antitumor immune responses. 4 DC are the most powerful professional antigen presenting cells which recognize tumor antigens, process then, and present antigenic peptides to the T-cells in conjunction with MHC class I or II molecules. 5 This results in activation and clonal expansion of specific CD4þ or CD8þT-lymphocytes and thus mounting specific immune attack against foreign antigens, including tumor specific antigens. In fact, it has been demonstrated that the numbers of tumor-associated DC positively correlate with a better patient prognosis and longer survival. 6, 7 In addition, administration of DC, pulsed with tumor antigens, in cancer patients has been shown to induce antitumor immunity and clinical responses in several clinical trials, including trials for prostate cancer patients. 8 However, we have recently shown that prostate cancer-derived factors not only cause apoptotic death of DC but also markedly inhibit the generation of DC in cultures. 9 Thus, physical or functional elimination of DC by tumor might effectively abolish the induction of antitumor immune responses and limit the efficacy of DC-based immunotherapies for prostate cancer.
It is likely that protection of DC from prostate cancerinduced apoptosis should prolong their survival in the tumor microenvironment and restore, at least in part, a suppressed host immune system. Several cytokines, including CD40L (CD154), IL-12, and IL-15 have been shown to increase the resistance of DC to tumor-induced apoptosis. 4, 10 However, although TNF-a plays a key role in the regulation of DC generation, differentiation and maturation, its role in protection of DC from tumormediated cell death has not yet been evaluated. TNF-a is a 17 kDa cytokine, consisting of 157 amino acids and exhibiting a variety of immunobiological functions. 11 Its proinflammatory and antitumor activity was first noticed more than 100 y ago, but the protein was only identified in 1975. 12 Its gene was cloned in 1984, 13 and it was mapped to the short arm of chromosome 6, 14 near the HLA-B focus in the MHC. TNF-a is mainly produced by the activated macrophages and monocytes, although DC, mast cells, neutrophils, keratinocytes, smooth muscle cells, intestinal paneth cells, tumor cells, and microglial cells might also produce and release TNF-a. 15, 16 Addition of TNF-a to DC cultures leads to increased DC generation and accelerated maturation, thus enhancing DC's antigen-presenting capacity and the ability to stimulate T cell proliferation. 17, 18 Since the dendritic cell system is markedly suppressed in cancer patients, 19 the search for new modalities to restore DC function and increase the efficacy of DC-based immunotherapies is of growing importance.
The aims of this study were to determine the influence of TNF-a on DC in the prostate cancer microenvironment in vitro, to compare the sensitivity of immature and mature DC to prostate cancer-induced apoptosis, and to evaluate the role of Bcl-2 protein expression in TNF-amediated protection of mature DC from tumor-induced cell death. We have found that the induction of DC maturation by TNF-a was accompanied by increased expression of the anti-apoptotic protein Bcl-2 and increased resistance of DC to prostate cancer-induced apoptosis in vitro. These data provide a new mechanism of tumor-induced apoptosis of DC and suggest a new approach to prolong the survival of DC in the tumor microenvironment which in turn might increase the efficacy of DC-based immunotherapies for prostate cancer.
Materials and methods

Mice and murine cell lines
Male C57BL/6 mice, 6 -8 weeks old, were obtained from Taconic (Germantown, NY). Animals were maintained at the Central Animal Facility at the University of Pittsburgh according to the standard guidelines. RM-1, a murine prostate cancer cell line, was a generous gift of Dr TC Thompson (Baylor College of Medicine, Houston, TX). Tumor cells were maintained in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine serum, 2 mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin, 1 mM sodium pyruvate, and 0.1 mM nonessential amino acids (GIBCO BRL, Grand Island, NY).
Generation of murine DC
Murine DC cultures were established as described earlier. 20 Briefly, bone marrow cells were depleted of red blood cells with lysing buffer (155 mM NH 4 Cl in 10 mM Tris -HCl buffer, pH 7.5, 25 C) for 2 -3 min. The single cell suspensions were then incubated with a cocktail of antibodies for 1 h at 4 C followed by incubation with rabbit complement for 30 min at 37 C to deplete cells that expressed the lymphocyte antigens B220, CD4, and CD8. Treatment with antibodies (Partially purified supernatant of hybridoma cell cultures TIB-146, TIB-207, and TIB-105, respectively) and complement removed detectable B and T lymphocytes from the cell suspensions. Cells were then cultured overnight (37 C, 5% CO 2 ) in 6-well plates (Falcon, Franklin Lakes, NJ) at a concentration of 10 6 cells/ml, in complete medium, consisting of RPMI 1640, 2 mM L-glutamine, 50 mg/ml gentamicin sulfate, 10 mM HEPES, 10% heat-inactivated fetal bovine serum, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate, 1 mg/ ml indomethacin (Sigma) and 50 mM N-methyl-L-arginine (Alexis, San Diego, CA). The non-adherent cells were then collected by gentle pipeting, counted and resuspended at a concentration of 10 5 cells/ml in complete medium supplemented with 1000 U/ml recombinant mouse GM-CSF and IL-4 (both were generously provided by Schering-Plough, Kenilworth, NJ). Cells were cultured in 6-well plates (4 ml/well) for 7 days at 37 C, 5% CO 2 . Non-adherent DC were collected by gentle pipeting and used for further studies.
To accelerate the maturation of murine bone marrowderived cultured DC, they were treated with murine TNF-a (R&D Systems Inc, Minneapolis, MN) at a final concentration of 10 ng/ml. TNF-a was added to DC cultures twice, on the fifth and sixth days of culture that is, 48 and 24 h prior to experiments.
Evaluation of apoptosis
Immature and mature DC were harvested after coincubation with tumor cells and placed on microscope slides for the morphological evaluation, using a Cytospin centrifuge (Shandon Lipshaw, Pittsburgh, PA). After drying for 5 min, cells were stained with a LeukoStat Stain Kit (Fisher Scientific, Pittsburgh, PA) and the percentage of apoptotic cells was assessed quantitatively using morphological criteria, which includes condensation of chromatin and reduction in nuclear size, shrinkage of total cell volume and increase in cell density, and formation of apoptotic bodies. 21 Annexin V binding assay. DC were collected and doublestained with FITC-conjugated Annexin V (Pharmingen, San Diego, CA) and/or propidium iodide (PI) (Sigma). Annexin V was added according to the manufacturer's recommendations. PI was used at a final concentration of 10 mg/ml. All Annexin V positive cells were considered apoptotic and their percentage was calculated among the total number of cells. Cells taking the vital dye PI were considered dead. Samples were analyzed by the FACScan flow cytometer with CellQuest 1.0 software package (BD, San Diego, CA).
TUNEL staining. Cells were collected, washed, counted, and 10 6 cells/ml were fixed consecutively in 4% formaldehyde and 80% ethanol. Fixed cells were placed onto glass slides using Cytospin centrifuge. TdT-FragEl DNA fragmentation detection kit (Oncogene Research Products, Cambridge, MA) was used for terminal deoxynucleotidyl transferase and nick translation (TUNEL) assay to determine the apoptosis. TUNEL positive and negative cells were counted in at least 10 different fields and the number of apoptotic cells was expressed as the percentage of TUNEL positive cells.
Western blot
The level of expression of anti-apoptotic protein Bcl-2 in cultured DC was examined using a Western blot technique. Briefly, DC were collected on the seventh day, washed in PBS and homogenized. The homogenate was centrifuged at 12 000 g for 15 min at 4 C. The protein concentration in the supernatant was determined by the Bradford method, using BioRad kit (Bio-Rad Laboratories, Hercules, CA). Each sample was denaturated for 5 min at 100 C in a sample buffer. Equal amounts of protein were loaded for each sample and electrophoretically separated on 16.5% SDS -PAGE followed by transfer to a nitrocellulose membrane. The membrane was blocked with 0.2% nonfat milk and 0.1% Tween-20 (Fisher) in 20 mM Tris -saline buffer at pH 7.2. Bcl-2 was detected using specific rabbit primary antibodies (Oncogene Research Products) with a final concentration of 2.5 mg/ml, and donkey anti-rabbit secondary antibodies (1:2000 dilution, Amersham Pharmacia Biotech Inc., Piscataway, NJ). In addition, expression of housekeeping protein b-actin was also determined using specific monoclonal antibody (Sigma). The membrane was processed and treated with chemiluminescence reagents (Tropix, Medford, MA). The bands were visualized on Kodak film and analyzed for average pixel value using UN-SCAN-IT TM gel (Version 5.1) software (Silk Scientific, Orem, UT).
Experimental design
After 7 days of culture, DC were collected and incubated with the murine prostate cancer cell line RM-1 in 6-well plates. Cells were separated using membrane inserts with 0.4 mm pore size, which excluded direct cell-to-cell contact, but allowed a free exchange of soluble substances. 5 -10 6 10 5 DC were placed in 6-well plates in 3 ml of medium. 2 6 10 6 prostate cancer cells resuspended in 2 ml of medium were placed into the inserts. As controls, DC were co-incubated with murine splenocytes or medium alone. DC were harvested 48 h later for the apoptosis assessment and Western blot analysis of protein expression. Four independent experiments were performed with the same results and mean data are presented.
Statistical analysis
w 2 analysis was performed to evaluate the significance of differences between the experimental groups in the Annexin V staining assays when discrete data were presented. For all analyses, the level of significance was set at a probability of 0.05 to be considered significant. All statistical calculations were performed using SigmaStat Statistical Software (SPSS, Chicago, IL). Data are presented as the mean AE standard error of the mean (s.e.m.).
Results
Prostate cancer cells induced the apoptosis of murine DC upon co-incubation Murine DC were generated in cultures and co-incubated with RM-1 cells across the 0.4 mm pore membrane. Murine splenocytes were used instead of tumor cells as a control. RM-1/DC ratio ranged between 4:1 and 2:1. DC were collected after 48 hours of co-incubation and number of apoptotic cells was assessed by the morphologic criteria, Annexin V binding assay and TUNEL staining. Based on morphological characteristics (Figure 1 ), the levels of apoptotic DC were 12.9 AE 2.49 and 29.02 AE 3.96% after co-incubation of DC with splenocytes and RM-1 cells, respectively (P ¼ 0.003). No significant differences were determined between DC cultures co-incubated with splenocytes or medium alone (P > 0.05). Results of the Annexin V binding assay revealed that apoptotic rate, determined as percentage of Annexin VþPI7cells, among DC incubated with splenocytes was 19.82 AE 1.93%, whereas the incubation with RM-1 cells induced apoptosis in 48.50 AE 2.65% of DC (Figure 2 ). Difference between these numbers was statistically significant (P < 0.001), suggesting that prostate cancer cells induce DC apoptosis 
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in vitro upon co-incubation even through the semipermeable membrane. Similar data were obtained using TUNEL staining: percentage of TUNEL positive cells in DC cultures co-incubated with tumor cells ranged from 30.96% to 46.35% (39.42 AE 3.56%), whereas the percentage of TUNELþcells was only 8.20 AE 1.95% and 12.05 AE 2.23% in DC cultures co-incubated with medium alone or splenocytes, respectively. Interestingly, no significant differences in the levels of DC apoptosis were observed when tumor cells were removed after 24 h of co-incubation and DC were cultured for additional 24 h (data not shown). This suggests that this time was sufficient for the apoptosis-triggering stimuli to be manifested in DC. Together these data confirmed our early findings and served as a basis to determine the effect of DC maturation on their sensitivity to prostate cancer-induced apoptosis.
Increased DC survival after the TNF-a-induced maturation
The DC were maturated with TNF-a stimulation on the fifth and sixth days of the culture and co-incubated with RM-1 cells or murine splenocytes on the seventh day. Non-stimulated (immature) DC served as controls. DC were collected after 48 h and an Annexin V assay or TUNEL staining were used to measure apoptosis. The results of these experiments demonstrated that the survival rates of mature DC in all conditions were significantly higher the survival rates of immature DC. For instance, incubation of TNF-a stimulated DC with splenocytes yielded an apoptotic rate of 14.08 AE 1.17%, whereas apoptosis was detected in 20.71 AE 2.88% of cells in the comparable immature DC cultures (P < 0.001). Results presented in Figure 3 demonstrate that co-incubation with prostate cancer cells leads to an increased death rate among mature DC (up to 22.55 AE 1.44%), although the level of apoptotic death was almost twice as high among the immature DC incubated with the same RM-1 cells (43.04 AE 2.08%) (P < 0.001). These results were confirmed using different apoptosis determination procedures. Thus, these data suggest that maturation of DC, induced by TNF-a, not only increases their survival in control cultures, but also significantly increases the resistance of DC to prostate cancer-induced apoptosis.
TNF-a abolished tumor-induced inhibition of the expression of Bcl-2 in DC
To evaluate the mechanism of TNF-a-mediated protection of mature DC from prostate cancer-induced apoptotic Figure 3 Treatment of DC with TNF-a resulted in the increased resistance of DC to prostate cancer-induced apoptosis. DC were generated, treated with TNF-a and co-incubated with RM-1 cells as described in the legend to Figure 2 . The percentages of apoptotic cells in DC cultures coincubated with splenocytes (control) or RM-1 tumor cells were determined by an Annexin V binding assay, as described in Materials and methods. Pretreatment of DC cultures with TNF-a (10 ng/ml) (grey bars) resulted in a significant inhibition of levels of apoptosis in comparison to non-treated cultures (black bars). *P < 0.001. death, we examined the expression of anti-apoptotic protein Bcl-2 in DC after stimulation with TNF-a. Cultured DC were treated with TNF-a twice for 48 h and nonstimulated DC served as a control. Interestingly, no increase in the expression of Bcl-2 in DC after the TNF-a treatment was detected when compared with control values (Figure 4 ). For instance, the average pixel value of Bcl-2 expression in TNF-a-treated DC reached 60.07 units compared to 60.51 units in non-stimulated DC. Next, Bcl-2 protein expression was determined in mature and immature DC after their co-incubation with RM-1 cells. As it can be seen in Figure 4 , co-incubation of non-stimulated immature DC with RM-1 cells resulted in a marked decrease in the expression of Bcl-2 protein in comparison to control DC co-incubated with splenocytes: 35.34 and 60.51 pixel units, respectively. This suggests that prostate cancer-derived factors markedly suppress the expression of the anti-apoptotic protein Bcl-2 in DC resulting in shorter cell survival in the tumor microenvironment. However, there was no detectable difference in the expression of anti-apoptotic protein between mature TNF-a-treated DC incubated with either splenocytes or prostate cancer cells, suggesting that TNF-a blocked tumor-induced suppression of Bcl-2 expression in mature DC. Thus, taken together these data demonstrate that RM-1 cells induce decreased expression of antiapoptotic protein Bcl-2 in DC leading to their apoptosis, whereas maturation of DC by TNF-a stabilized the expression of Bcl-2 and provided DC with protection against prostate-cancer induced apoptosis.
Discussion
Immunotherapy is emerging as one of the major areas of exploration as both an experimental treatment and a clinical trial for prostate cancer. DC have been used for prostate cancer patients with significant success, when autologous peptide-pulsed DC were administered systematically. 22 Response rate accounted for over 30%. 23 In addition, immunological monitoring documented enhanced cellular immunity in patients treated with peptide-pulsed DC. 3 However, the majority of treated prostate cancer patients were resistant to DC-based immunotherapies, suggesting that this approach should be further improved. 8 As it has been shown, DC numbers decrease in prostate cancer tissues in comparison to benign prostatic hyperplasia (BPH) tissues 24 and the levels of infiltrating DC further decreases with the increase of anaplastic grade. 25 Our previous experiments demonstrated that prostate cancer cells induced apoptosis of human DC during the in vitro co-incubation. 4 Since DC play a crucial role in the mounting of host antitumor immune responses, 5, 26 it is conceivable that their elimination might effectively suppress the immune system. Therefore, it is likely that protection of DC from tumorinduced apoptosis should improve the host immunity and enhance the antitumor responses. Several cytokines have been shown to regulate the survival of DC. 27 GM-CSF and CD40L are well known DC survival factors which can markedly prolong DC lifespan in in vitro cultures. We have recently demonstrated that CD40L, IL-12 and IL-15 could also protect DC from tumor-induced apoptosis. 4, 10 However, the role of TNF-a, another well-known DC growth factor, in the regulation of DC survival in the tumor microenvironment was not yet characterized. TNF-a is a proinflammatory and cytotoxic agent and is known mainly for its capacity to induce cell death. 28, 29 However, TNF-a and other members of its family (TRANCE, TRAIL, TRAP, etc.) may act as both cell protectors and apoptosis inducers. 30, 31 The influence of TNF-a influence on DC was noticed several years ago when it was suggested that TNF-a has a pivotal role in DC generation. 32, 33 TNF-a has been widely used for in vitro DC production in combination with GM-CSF. 33 -35 It is also possible that TNF-a can be crucial for DC survival in cultures. 30, 36 Apparently, DC are also able to produce TNF-a 35, 37 and were even considered as a major source of TNF-a, in addition to macrophages. 38 Production of TNF-a by DC or addition of TNF-a to DC cultures greatly enhances numbers of DC and the level of their maturation as determined by the increased expression of surface molecules MHC class I and II, CD83, CD80 (B7-1), and CD86 (B7-2). 17, 18, 30 It has also been reported that TNF-a-stimulated DC demonstrate an 8-fold increased capacity to stimulate T cell proliferation in an MLR assay, and their antigen-presenting capacity is also increased 10 -100 fold. 17 TNF-a also promotes DC migration activity. 39, 40 Here we have demonstrated that TNF-a protects DC from prostate cancer-induced apoptotic death in vitro. In our system, TNF-a performed protective functions probably by stabilizing the expression of anti-apoptotic protein Bcl-2. It has been recently shown that TNF-a influence on the Bclfamily of proteins might also vary from inhibition to stimulation depending on the cell type and other factors: TNF-a could decrease or slightly increase the expression of Bcl-2 family proteins 41, 42 or may enhance the expression of pro-apoptotic protein Bax, 41 though not in all systems. 42 We did not detect any marked change in Bax Figure 4 TNF-a prevents prostate cancer-induced inhibition of Bcl-2 expression in DC. DC were generated, treated with TNF-a and coincubated with RM-1 cells as described in the legend to Figure 2 and the expression of anti-apoptotic protein Bcl-2 and housekeeping protein b-actin in DC was determined by Western blot, as described in Materials and methods. Note decreased expression of Bcl-2 in DC following the coincubation with RM-1 prostate carcinoma cells. Treatment of DC with TNF-a (10 ng/ml) before the co-incubation with RM-1 cells prevented a suppression of Bcl-2 expression. Results from one representative experiment are shown.
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In summary, TNF-a leads to the maturation of DC in cultures, it enhanced their anti-apoptotic features and protected DC from prostate-cancer induced apoptosis. Therefore, use of TNF-a-stimulated DC in the treatment of prostate cancer might enhance the efficacy of DC-based therapy, since mature DC are more active in presenting antigen and stimulating T-cells in addition to being relatively impervious to prostate cancer-induced apoptosis. The only concern is the reported decrease in the capacity of the mature DC to uptake antigen. 43, 44 We also detected a measurable decrease in phagocytic activity of the TNF-stimulated DC in comparison to immature cells, although more than 50% of mature DC were still able to efficiently uptake antigen (data not shown). Therefore, it is possible to suggest that during the experimental therapy or DC-based clinical trials, DC should either be loaded with peptides before or during their maturation, or, when direct intratumoral injection is preferred, a sufficient number of mature DC need to be injected to induce an effective antitumor immune response.
